Table 3.

Summary of the meta-analyses done to assess therapeutic efficacy of umbilical cord-derived stem cell transplantation in subjects who received intervention compared to control subjects who did not receive that intervention

Study name and year	Number of subjects	SC group		Number of subjects	Control group		Study weight	SMD	Lower CI	Upper CI	Type of DM	Type of UC-SC
		Mean	SD		Mean	SD
HbA1c%
Hu et al., 2013	15	6.100	1.100	14	7.400	1.900	18.7	− 0.821	− 1.580	− 0.063	T1DM	WJ-MSCs
Hu et al., 2016	31	6.000	0.700	30	7.100	0.800	22.5	− 1.446	− 2.010	− 0.883	T2DM	WJ-MSCs
Cai et al., 2016	21	7.500	1.000	21	8.800	0.900	20.4	− 1.341	− 2.010	− 0.671	T1DM	WJ-MSCs
Chen et al., 2016	6	6.820	0.530	6	7.820	0.310	9.6	− 2.125	− 3.541	− 0.710	T2DM	WJ-MSCs
Haller et al., 2013	10	7.100	1.290	5	7.400	0.400	13.5	− 0.258	− 1.335	0.820	T1DM	UCB
Giannopoulou et al., 2013	7	7.250	0.440	10	7.225	1.070	15.2	0.027	− 0.939	0.993	T1DM	UCB
C-peptide levels (ng/ml)
Hu et al., 2013 a	15	1.350	0.230	14	0.810	0.300	16.9	1.973	1.085	2.861	T1DM	WJ-MSCs
Hu et al., 2016 a	31	2.660	0.330	30	1.670	0.250	17.3	3.331	2.555	4.106	T2DM	WJ-MSCs
Cai et al., 2016 a	21	0.060	0.030	21	0.030	0.020	17.7	1.154	0.501	1.808	T1DM	WJ-MSCs
Chen et al., 2016 c	6	0.700	0.380	6	0.220	0.130	15.4	1.560	0.267	2.852	T2DM	WJ-MSCs
Haller et al., 2013 b, *	10	0.163	0.181	5	0.207	0.211	16.2	− 0.217	− 1.293	0.859	T1DM	UCB
Giannopoulou et al., 2013 b	7	0.390	0.388	10	1.032	0.800	16.5	− 0.914	− 1.928	0.099	T1DM	UCB

^aFasting C-peptide

^bStimulated peak C-peptide

^cStimulated early phase C-peptide secretion function ΔCP30/ΔG30

^*Measuring unit; pmol/L